ICLE 2022 | PiggyBac Transposon-generated CAR T-cells in solid tumors

Shigeki Yagyu, MD, PhD, Kyoto Prefectural University of Medicine, Kyoto, Japan, discusses the future of PiggyBac transposon-mediated chimeric antigen receptor (CAR) T-cell therapies. A clinical trial is imminently underway to assess a CAR T-cell therapy based on PiggyBac transposon technology in HER2+ bone sarcoma and gynecological cancers. Preclinical studies assessing the treatment has yielded promising results in sarcoma and brain tumors in terms of efficacy and long-term functionality. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.